PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24886434-5	2014	RESULTS: Treatment of isolated tumor cells from the ascites of ovarian cancer patients and HEY ovarian cancer cell line with paclitaxel resulted in a CSC-like residual population which coincided with the activation of Janus activated kinase 2 (JAK2) and signal transducer and activation of transcription 3 (STAT3) pathway in paclitaxel surviving cells.	Paclitaxel	125-135	signal transducer and activator of transcription 3	Homo sapiens	254-305	
24886434-5	2014	RESULTS: Treatment of isolated tumor cells from the ascites of ovarian cancer patients and HEY ovarian cancer cell line with paclitaxel resulted in a CSC-like residual population which coincided with the activation of Janus activated kinase 2 (JAK2) and signal transducer and activation of transcription 3 (STAT3) pathway in paclitaxel surviving cells.	Paclitaxel	125-135	signal transducer and activator of transcription 3	Homo sapiens	307-312	
24886434-6	2014	Both paclitaxel-induced JAK2/STAT3 activation and CSC-like characteristics were inhibited by a low dose JAK2-specific small molecule inhibitor CYT387 (1 muM) in vitro.	Paclitaxel	5-15	signal transducer and activator of transcription 3	Homo sapiens	29-34	
24886434-9	2014	These results were consistent with significantly reduced activation of JAK2 and STAT3 in paclitaxel and CYT387-treated cell-derived xenografts compared to paclitaxel only-treated cell derived xenografts.	Paclitaxel	89-99	signal transducer and activator of transcription 3	Homo sapiens	80-85